HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brain Gain: Supplements And Nutraceuticals Expand Cognitive Health Science

This article was originally published in The Tan Sheet

Executive Summary

The next generation of substances to slow cognitive decline and perhaps even prevent Alzheimer's disease may take a test run through the dietary supplement and nutraceutical markets

You may also be interested in...



Quincy Bioscience receives investment

A capital infusion from the investment group DaneVest Tech Fund I will help Quincy Bioscience market its "novel" dietary supplement Prevagen, the Madison, Wis.-based biotech announces Aug. 25. Quincy launched the brain cell protection supplement in 2007 and says the unquantified investment "will accelerate our goal to make Prevagen a national brand" (1"The Tan Sheet" Aug. 10, 2009). Prevagen's active ingredient apoaequorin comes from jellyfish and is a calcium-binding protein that helps buffer excess calcium from damaging aging neurons, Quincy says

Bioenergy Rides Pharma Science Down Rx, Supplement Roads

Bioenergy Life Science exemplifies what many believe is the future of the nutritional industry - a firm steeped in science with feet in the supplement and pharmaceutical areas

Nutrient Formulation Improves Verbal Recall In Mild Alzheimer's Patients

A multi-nutrient drink under development by Group Danone improved memory in patients with mild Alzheimer's disease, according to a 12-week randomized, double-blind controlled trial with 225 "drug-naive" Alzheimer's patients

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel